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Introduction: The purpose of this study was theevaluation of synovial effusion (SE), synovial fluid (SF) and synovial
tissue (ST) biomarkers in relation to disease activity indexes to assess the response to intraarticular (IA) tumor
necrosis factor (TNF)-a blockers in psoriatic arthritis (PsA).
Methods: Systemic and local disease activity indexes (disease activity score (DAS); the Ritchie articular index (mRAI),
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); Thompson articular (THOMP) and joint articular
(KJAI)-Index ) and ST samples were assessed at baseline, throughout treatment, and during the follow-up in 14
patients affected with PsA who underwent IA injections (0.5 ml to 12.5 mg) in the knee joint of etanercept (E) or
placebo (P) once every two weeks for a 10-week period. Total SF white blood cell (WBC) counts (WBC/μl) and SF
cytokine/chemokine (CK/CCK) levels were measured before IA-E at baseline, after IA-E, and as long as there were
adequate amounts of SF for knee aspiration (post). Characterization of synovial mononuclear cell infiltration and
synovial vessels was carried out in 8 out of 14 knees by staining serial sections of synovial tissue biopsies for CD45,
CD3, CD68, CD31 and CD105.
Results: At baseline, CRP and/or ESR were significantly correlated with SF-CK (interleukin- (IL-)1b, IL-1Ra, IL-6, IL-8)
and CCK (CCL3). Post-IA injections, there was a decrease in SE in the knees in which aspiration following IA-E
injection was possible as well as a significant reduction in SF WBC/μl and in SF-CK (IL-1b, IL-1Ra, IL-6 and IL-22).
Pre- and post-IA-E injections, there were significant correlations between ST markers and SF-CK (IL-1b with CD45;
IL-1b and IL-6 with CD31) and between SF-CCK (CCL4 and CCL3 with CD3). At the end of the study, there was a
significant reduction in disease activity indexes (CRP, DAS, RAI, THOMP, KJAI) as well as in the ST markers (CD45;
CD3).
Conclusions: Synovial effusion regression is a reliable indicator of the response to IA TNF-a blockers in PsA
patients as it is confirmed by the correlation between SF biomarkers to disease activity and synovial tissue
inflammation.
Introduction
Actively inflamed joints in psoriatic arthritis (PsA)
patients unresponsive to systemic treatments [1] show
comparable levels of functional [2] and radiological dis-
ease progression [3] compared to those in rheumatoid
arthritis (RA).
Prominent vascular alterations just beneath the lining
cell layer, reduced layer lining thickness, and lower CD68
expression are distinctive features of PsA synovitis
with respect to RA [4,5]. Tumor necrosis factor-alpha
(TNF-a) plays an important role in the chronic inflam-
mation found in PsA patients, and its increased expres-
sion together with that of other pro-inflammatory
cytokines, including interferon-g (IFN-g), interleukin (IL)
-12, IL-15, IL-17 and IL-18, and in particular, IL-6 and
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Disease-related cytokines in synovial tissue may also pro-
mote osteoclast formation resulting in bone erosion [8].
While the efficacy of TNF-a-blocking agents in redu-
cing disease activity in PsA patients [9,10] has been
demonstrated, their actual mechanisms of action are not
completely understood [11-13]. Recent research has
made it possible to identify new genetic factors [14,15]
and immunopathological mechanisms common to psor-
iasis and psoriatic joint inflammation [16,17].
Genetic risk factors have implicated the interleukin
(IL)-23 pathway and the induction and regulation of
type 17 T-helper (TH-17) cells in the pathogenesis of
psoriasis [18,19]. Secretion of cytokines, such as IL-22
and IL-17, could, moreover, induce keratinocyte prolif-
eration and skin inflammation [19,20].
Biomarkers have been used as surrogate treatment
endpoints in preliminary, short-term, proof-of-concept
studies [21], but only limited data concerning biological
biomarkers in psoriasis and psoriatic arthritis are avail-
able. It has been seen that histological findings are not
correlated with clinical disease parameters [5]. The
expressions of RANK ligand and osteoprotegerin (OPG)
are similar in non-psoriatic spondyloarthropathy (SpA)
as compared to PsA spondyloarthropathy [8], but
neither are related to the degree of systemic or local
inflammation, nor are they significantly modulated by
effective response to TNF-a blockers [16,22]. The need,
therefore, of reliable biomarkers to assess disease pro-
gression in PsA is clearly indisputable [21].
The aim of this longitudinal study was to investigate
synovial effusion (SE), synovial fluid (SF) and synovial
tissue (ST) biomarkers in relation to local and systemic
disease activity biomarkers to assess the outcome of
intra-articular (IA) TNF-a blockade therapy on gonar-
thritis in PsA patients [23-25].
Materials and methods
IA-treatment was assessed by means of a single blind
comparison between IA-etanercept (E) and IA-placebo
(P), administered once every two weeks for a 10-week
period in all those patients not needing to drop-out
because of drug inefficacy, with a cross-over after the
first IA injection. Those needing to drop-out were
included in the open-label extension part of the study
during which four IA-E injections were administered
once every two weeks. Each 0.5 ml IA-injection (E:
12.5 mg, placebo: NaCl) was administered in individual
knee joints after synovial fluid aspiration. The mean
cumulative IA-E dosage for all of the patients was
50 mg for both the blind and open-label extension
study. The study protocol (Etanercept/TNR-001:n.878P)
was approved by the local ethics committee (Padova,
20 September 2004) and all patients signed consent
statements after being informed about the intent and
the methodology of the study [26].
PsA was defined as the presence of both psoriasis and
inflammatory arthritis, regardless of their rheumatoid
factor (RF) status. All 14 patients participating in the
study fulfilled the CASPAR (CLASsification criteria for
Psoriatic ARthritis) classification criteria for PsA [27].
The psoriasis area and severity index (PASI) was less
than 10 in these patients. Affected with active gonarthri-
tis, which was characterized by pain, tenderness, and
effusion, all of the patients were being treated with
stable DMARD, steroid, and/or E systemic therapy.
Assessment
Patients’ responses to therapy were blindly assessed by
the same investigator (LC).
SF cell counts (C/μl) were performed on all of the
samples aspirated before IA-E injection throughout the
entire study.
The primary efficacy endpoint utilized was the knee
Thompson Articular Index (THOMP) [28], a sum of
scores for each knee joint concerning pain on move-
ment (0 to 3), soft tissue swelling (0 to 3) and warmth
(0 to 3); (range 0 to 9). The secondary efficacy endpoint
was: the Knee Joint Articular Index (KJAI), already vali-
dated in RA, PsA, and SpA-Knee Joint Synovitis (KJS)
patients, likewise a sum of scores (0 to 14) for tender-
ness (0 to 3), joint swelling (0 to 3), the ballottement of
patella or the bulge sign (0 to 2), the range of knee joint
flexion (0 to 3) and extension (0 to 3) [29].
The systemic secondary endpoints were: (i) The modi-
fied Ritchie Articular Index (mRAI), a sum of scores
assessing 30 joints for tenderness (0 to 3) including
hand and foot Distal Interphalangeal Joints (DIP) with
each side considered as a group score (DIP involvement
is often observed in oligo-and poli-PsA patients) [30]
and the Disease Activity Score (DAS). (ii) Erythrocyte
Sedimentation Rate (ESR) (≤ 28 mm/h) and serum
C-reactive Protein (CRP) values (≤ 0.5 mg/dl) were
assessed at baseline and at the end of the study.
Synovial fluid biomarkers
SF samples, aspirated from knee joints before the first
IA-E injection, at baseline, and before each IA-E injec-
tion, were collected and frozen at -80°.
The post-treatment synovial effusion was defined as
the last SF sample available for aspiration after one or
more IA-E injections in each knee. The last SF sample
available from each knee (post-treatment) underwent
synovial effusion analysis. The SF samples were analysed
for total white blood cell (WBC) counts (WBC/μl). The
cytokines: IL-1b, IL-1 receptor antagonist (IL-1Ra), IL-6,
IL-17, TNF-a,I F N - g, the CXC chemokine IL-8, the CC
chemokines, CCL2, the monocyte chemoattractant
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tory protein (MIP-1a) and CCL4, the macrophage
inflammatory protein-1b (MIP-1b), were measured
using a commercially available multiplex bead immu-
noassay, based on the Luminex platform (Fluorokine
MAP Multiplex Human Cytokine Panel A, R&D
Systems, Minneapolis, MN, USA) following the manu-
facturer’s instructions. Normal serum values were those
established in 50 healthy blood donors. IL-22 was mea-
sured using a commercially available ELISA kit (Quanti-
kine Human IL-22, R&D Systems). SF was centrifuged
before determinations were made at 1,000 g to remove
cells and debris.
Synovial biopsy
Synovial biopsies were carried out during arthroscopy
while patients were under the effect of anaesthesia, no
earlier than two weeks before the first IA-E injection
and no later than two to four weeks after the last one.
Synovial specimens were obtained targeting the areas of
intense synovial hyperemic proliferation. Multiple biopsy
samples from each patient were stored in paraformalde-
hyde and embedded en bloc in paraffin.
Immunohistochemistry
Characterization of synovial mononuclear cell infiltra-
tion and synovial vessels was carried out in consecutive
serial sections of synovial biopsies obtained from eight
patients before the first and after the last IA-E injection.
In particular they were immunostained by using the fol-
lowing antibodies: CD3 (Novocastra, Newcastle Upon
Tyne, UK), CD68, CD45 (clone 2B11), CD31 (clone
JC70A), CD105 (SN6h) (Dako Cytomation, Glostrup,
Denmark). All the parameters were measured by
computer-assisted morphometric analysis (Image Pro-
plus version 5) and a 2 mm square area was evaluated.
Statistical analysis
Mean and standard deviations were used as descriptive
statistics. Changes over time of selected outcomes and
biological markers after IA-E treatment were evaluated
using the non-parametric Wilcoxon Signed Rank test.
All analyses were performed using SPSS software (SPSS
15.0 (SPSS Inc., Chicago, IL, USA). The Spearman Rank
test was used for correlation analysis.
Results
The main clinical details as well as systemic disease activ-
ity indexes of all patients are listed in Table 1. Four PsA
patients were being treated with parenteral E from the
time of screening to the end of the IA treatment period.
SF samples were aspirated immediately before the first
IA injection from all 14 knees. There was a decrease in
SE in the knees in which aspiration following IA-E
injection was possible. In 10 knees the effusion
disappeared before the fifth IA-E injection (Figure 1).
There was a statistically significant reduction in synovial
fluid WBC/μl when pre and post IA-E values were com-
pared. (Figure 2a).
The Thompson Articular Knee Index values were
significantly reduced (Figure 2b) in the 14 knees at the
post-treatment assessment (at the time the last SF sam-
ple was available) as well as at the end of the study (two
weeks after the last IA-E injection), and there were no
differences in the results between these two points in
time.
Table 1 Clinical, demographic characteristics and systemic disease activity indexes of psoriatic arthritis patients
Knee Disease duration (years) Gonarthritis duration (years) Treatment at study entry ESR CRP DAS mRAI
PRE POST PRE POST PRE POST PRE POST
1 10.3 10.3 MTX; PN 46.4 88.4 1.78 0.33 3.21 3.42 8 8
2 8.4 6.4 PN;MTX; CSA; E 40.3 29.0 2.77 0.72 3.44 3.33 12 12
3 12.5 10.5 PN 23.2 22.2 0.53 0.02 2.33 1.25 3 0
4 8.6 8.6 LEF;E 72.5 33.8 0.56 0.56 2.78 2.59 4 4
5 22 5.7 PN 12.0 13.0 0.85 0.53 2.88 2.47 6 5
6 11 11 MTX 15.6 22.7 0.10 0.00 2.69 3.00 7 9
7 9 9 SSZ 15.0 11.0 0.66 0.39 3.18 2.42 12 5
8 6.5 4.3 MTX; PN; E 6.0 9.9 0.32 0.80 2.65 1.87 10 2
9 4 3.5 MTX; SSZ 18.1 3.6 2.93 0.24 2.52 0.71 5 0
10 9 15 CSA; PN; E 30.0 20.0 0.00 0.00 3.01 2.40 2 1
11 4.8 4.5 MTX; CSA 29.4 25.2 0.08 0.08 2.48 1.89 4 1
12 2.5 2.5 MTX; PN 14.3 6.8 0.70 0.20 3.97 3.40 20 18
13 8.5 2 SSZ; MTX 41.2 27.2 0.48 0.14 2.77 1.98 3 1
14 5.5 3.5 SSZ 13.6 2.2 0.26 0.26 3.22 0.75 9 0
CRP, C-reactive protein (≤ 0.5 mg/dl); CSA, cyclosporin; DAS, disease activity score; E, etanercept; ESR, erythrocyte sedimentation rate (≤ 28 mm/h); HCQ,
hydroxychloroquine; LEF, lefluonomide; mRAI, modified Ritchie articolar index; MTX, methotrexate; PN, prednisone; PsA, psoriatic arthritis; Pt, patient; SSZ,
sulphasalazine.
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gical (CRP: 0.86 ± 0.95 and 031 ± 0.26, P =0 . 0 1 9 )a n d
clinical (DAS: 2.93 ± 0.43 and 2.24 ± 0.90, P =0 . 0 0 2 ,
mRAI: 7.50 ± 4.88 and 4.71 ± 5.37, P =0 . 0 1 1 )d i s e a s e
activity indexes was observed at the end of the study, as
well as statistically significant reduction of local composite
(THOMP; KJAI) disease activity indexes at the post-treat-
ment assessment (Figure 2b, c) and the end of the study.
Pre-treatment IFN-g was undetected in all the SF sam-
ples at baseline and throughout the study. Several cyto-
kines/chemokines (IL-1b, IL-1Ra, IL-6, IL-8, MCP-1/
CCL2, MIP-1a/CCL3 and MIP-1b/CCL4 as well as IL-
17 and IL-22) were detected.
There were significant correlations in some pre-treat-
ment systemic and biological disease activity indexes and
specifically between CRP and IL-1b,I L - 1 R a ,I L - 6S F
levels as well as between ESR and IL-1b, IL-1Ra, IL-8 and
MIP-1a/CCL3 SF levels (Table 2). There were, moreover,
significant correlations in the IL-1b, IL-6, IL-1Ra SF bio-
markers, which were correlated to one another. There
was also a correlation between IL-22 and TNF-a.B o t h
IL-8 and IL-6 were correlated to MIP-1a/CCL3 and
MIP-1b/CCL4, respectively. Finally, MCP-1/CCL2, IL-
1Ra and MIP-1a/CCL3 were correlated to one another.
There was a statistically significant reduction in post-
treatment IL-1b, IL-1Ra, IL-6 and IL-22 levels with
respect to basal values (Figure 3).
A significant correlation was observed at baseline
between IL-1b and CD45. Both IL-1b and IL-6 were
correlated with CD31. There was a correlation between
MIP-1b/CCL4 and CD3-ST pre-injection values and
between MIP-1a/CCL3 and CD3-ST post-injection
levels. TNF-a blockers induced a significant down-
regulation in CD45 (1157.0 ± 712.9 and 545.8 ± 253.2,
P = 0.007) and CD3 (402.8 ± 203.0 and 224.8 ± 107.7,
P = 0.039) ST expression.
Discussion
The aim of this longitudinal study was to evaluate
S E ,S Fa n dS Tb i o m a r k e r st oa s s e s st h er e s p o n s et o
intra-articular TNF-a blockade therapy in PsA patients.
The study’s most striking finding was that synovial effu-
sion disappeared in the knees of PsA patients, indicating
that the therapy was effective. Its regression in the
Figure 1 Follow-up of synovial fluid effusion during IA-E
treatment.
Figure 2 SF total white blood cells and knee clinical indexes
before and after intra-articular TNF-a blockade. Synovial fluid
total white blood cells (a) Thompson Articular Knee Index (b) and
Knee Joint Articular Index (c) in 14 PsA patients before and after
intra-articular TNF-a blockade: pre, at baseline; post, at the time the
last synovial fluid sample was available for aspiration after one or
more IA-E injections in each knee. Significance by Wilcoxon rank test.
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the significant reduction in synovial fluid WBC counts
as well as in the SF-CK (TNF-a, IL-1b, IL-1Ra, IL-6 and
IL-22) indicate that IA-E injections have a local effect
on synovial inflammation.
The delay in the response of several knees of PsA
patients after IA TNF-a blockade, may indicate that
drug dosage was insufficient to control local knee
disease activity.
The expression of proinflammatory cytokine/chemo-
kine at baseline in the SF of the PsA patients is consistent
with previous findings in the SF [31,32] and in the ST
[5-7,11,33] of these patients. IL-6 concentrations were
similar in the SF of RA and SpA to PsA [34] while higher
IL-17 levels were observed in the SF of SpA to PsA
[35-37]. At baseline, IL-1b was correlated to IL-6 levels
in SF as well as to CD45 expression in ST and MIP-1 b/
CCL4 was correlated to post CD3 expression in ST.
High circulating [38] and SF levels of (MCP-1)/CCL2
have been observed in RA, PsA and SpA patients
[34,39,40] and were also associated to the response to
etanercept in RA patients [41]. In PsA, localized CCL2
production was correlated to the T cell infiltration of
PsA synovium [42]. In accordance with previous reports,
our findings in the SF of PsA patients support the
hypothesis that (MCP-1)/CCL2, MIP-1a/CCL3 and
MIP-1b/CCL4 chemokines play an important role in
PsA development [43].
Elevated IL-22 expression in the SF of PsA patients, a
novel finding in our patients, suggests that the Th17
Table 2 Correlations between synovial fluid biomarker
levels and biological disease activity indexes at baseline
in 14 knees










Significance by Sperman’s rank test: * P < 0.05; ** P < 0.01; ns, not significant.
Figure 3 Synovial fluid cytokines levels in 14 PsA knees before and after intra-articular TNF-a blockade. pre, at baseline; post, at the last
SF sample available for aspiration after IA-E injections. Significance by Wilcoxon rank test.
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joint involvement. The potential proinflammatory function
in joints of IL-22, a cytokine of the IL-10 family, has been
suggested by IL-22 mRNA expression by macrophages and
fibroblasts, by MCP-1/CCL2 production and fibroblast
proliferation of RA patients [44] and by the promotion of
osteoclastogenesis in collagen induced arthritis [45].
Alterations in CD45 and CD3 ST expressions are in
agreement with the decrease in the global cellular infil-
tration and T-lymphocytes, already found to be asso-
ciated with active systemic anti TNF-a treatment in
both Ra and PsA [46-48].
With regard to serum biological biomarkers, IL-6, IL-
r a ,I L - 1 0a n dE S Rh a v eb e e ns t u d i e di nP s A ,b u to n l y
IL-1ra and ESR have been found to reflect disease activ-
ity [49,50]. ESR and C-reactive protein were found to be
closely correlated to TNF-a blockade response [51,52],
but not to cytokine levels [21].
No previous study has evaluated the correlation
between SF biomarkers and systemic and local compo-
site disease activity indexes in PsA patients [53,54].
Synovial fluid analysis carried out in our patients during
this study indicates that SF biomarkers are correlated to
ST inflammation markers and to local and systemic
indexes of disease activity in PsA.
Serum IL-17 does not seem to be influenced by TNF-a
blockade following etanercept and infliximab both in
SpA and in RA [35,55]. According to experimental data,
TNF-a may lead to an increased activity of other proin-
flammatory pathways [56-58]. The fact that IL-22 and IL-
17 do not react in the same way in the SF of PsA would
seem to indicate that they have distinct regulatory path-
ways [59,37] and different cellular sources [60-62].
This study has important limitations: use of monovariate
statistical methods, the limited number of patients studied,
the concomitant DMARD treatment, the differences in the
drug doses utilized, and the number of injections adminis-
tered. Larger, controlled studies are, therefore, clearly war-
ranted to further assess their clinical relevance.
Conclusions
Regression of synovial effusion is a reliable indicator of the
response to intra-articular TNF-a blockade therapy in PsA
patients as it is confirmed by the correlation of SF biomar-
kers to disease activity and synovial tissue inflammation.
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